Kretzschmar A, Köhne C H, Dörken B
Abteilung für Hämatologie, Onkologie und Tumorimmunologie, Robert-Rössle-Klinik, Virchow-Klinikum, Medizinische Fakultät Charité der Humboldt-Universität zu Berlin.
Med Klin (Munich). 1997 Sep 15;92 Suppl 4:16-22. doi: 10.1007/BF03041971.
PHASE-II-STUDIES: Docetaxel (Taxotere; Rhône-Poulenc Rorer) was evaluated in the treatment of a wide range of tumors in the early nineties. This overview relates mainly to the results of 32 phase-II-studies from Europe, North America and Japan including the following malignancies: head and neck cancer, cancer of the ovary and cervix uterus, soft tissue sarcomas, gastrointestinal cancers, renal and transitional cell cancer as well as melanoma and glioma. Results of recent studies also revealed a high activity of combination chemotherapy with cisplatinum in untreated head and neck cancer as well as ovarian cancer.
A remarkable single agent activity was observed in the palliative treatment after recurrence of head and neck tumors (ORR 27 to 42%) and as salvage chemotherapy after failure of platinum compounds in ovarian cancer, where Docetaxel appeared to be similarly active as Paclitaxel and Topotecan. Remarkable activity was also observed in the treatment of gastric, pancreatic and urothelial cancer as well as melanoma.
Docetaxel ist a new cytotoxic drug with a broad range of activity in various solid tumors. The place of this compound in relation to established regimens and its value its value in combination chemotherapy warrants further investigation.
II期研究：多西他赛（泰索帝；罗纳普朗克-乐安公司）在20世纪90年代初被用于评估对多种肿瘤的治疗效果。本综述主要涉及来自欧洲、北美和日本的32项II期研究结果，这些研究涵盖以下恶性肿瘤：头颈癌、卵巢癌和子宫颈癌、软组织肉瘤、胃肠道癌、肾癌和移行细胞癌以及黑色素瘤和神经胶质瘤。近期研究结果还显示，顺铂联合化疗在未经治疗的头颈癌和卵巢癌中具有高活性。
在头颈肿瘤复发后的姑息治疗中观察到显著的单药活性（客观缓解率为27%至42%），在卵巢癌中作为铂类化合物治疗失败后的挽救化疗时，多西他赛似乎与紫杉醇和拓扑替康具有相似活性。在胃癌、胰腺癌、尿路上皮癌以及黑色素瘤的治疗中也观察到显著活性。
多西他赛是一种新型细胞毒性药物，在多种实体瘤中具有广泛活性。该化合物相对于既定治疗方案的地位及其在联合化疗中的价值值得进一步研究。
